ASPE
NASDAQAspen Neuroscience Inc.
Aspen Neuroscience Inc. (ASPE) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for ASPE, including 6 insider trades and 4 13D/G filings. The most recent was published Nov 6, 2026.
Price$12.57-0.93 (-6.89%)
2026-10-302026-11-06
News · 26 weeks10+100%
2026-05-102026-11-01
Mix1090d
- Insider6(60%)
- 13D/G4(40%)
Activity · 52 weeks103 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
10 items- 13D/GSEC Form SCHEDULE 13D filed by Aspen Neuroscience Inc.SCHEDULE 13D - Aspen Neuroscience, Inc. (0002124080) (Subject)
- 13D/GSEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.SCHEDULE 13G - Aspen Neuroscience, Inc. (0002124080) (Subject)
- 13D/GSEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.SCHEDULE 13G - Aspen Neuroscience, Inc. (0002124080) (Subject)
- INSIDERDirector Thompson Peter A. converted options into 2,589,132 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)4 - Aspen Neuroscience, Inc. (0002124080) (Issuer)
- INSIDERDirector Orbimed Advisors Llc converted options into 2,589,132 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)4 - Aspen Neuroscience, Inc. (0002124080) (Issuer)
- 13D/GSEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.SCHEDULE 13G - Aspen Neuroscience, Inc. (0002124080) (Subject)
- INSIDERLarge owner Arch Venture Fund X, L.P. bought $19,999,995 worth of shares (1,333,333 units at $15.00) and converted options into 2,421,589 shares (SEC Form 4)4 - Aspen Neuroscience, Inc. (0002124080) (Issuer)
- INSIDERLarge owner Arch Venture Partners Xiv, L.P. bought $18,000,000 worth of shares (1,200,000 units at $15.00) (SEC Form 4)4 - Aspen Neuroscience, Inc. (0002124080) (Issuer)
- INSIDERDirector Spaventa Andrew converted options into 250,415 shares (SEC Form 4)4 - Aspen Neuroscience, Inc. (0002124080) (Issuer)
- INSIDERExecutive Chair Hasnain Faheem converted options into 36,349 shares (SEC Form 4)4 - Aspen Neuroscience, Inc. (0002124080) (Issuer)
ASPE FAQ
7 questionsWhat does Aspen Neuroscience Inc. do?
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with high unmet medical need.What is the latest news on ASPE?
In the last 30 days Quantisnow tracked 10 wire items for ASPE: 6 insider trades and 4 13D/G filings. The most recent was published on November 6, 2026.Where does ASPE stock trade?
Aspen Neuroscience Inc. (ASPE) is listed on NASDAQ.What sector and industry is ASPE in?
Aspen Neuroscience Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aspen Neuroscience Inc. go public?
Aspen Neuroscience Inc. (ASPE) completed its IPO in 2026.What companies are similar to ASPE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ASPE side-by-side with any of them on Quantisnow.How can I track ASPE on Quantisnow?
Quantisnow aggregates Aspen Neuroscience Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ASPE to receive live email and push alerts on every new disclosure.